Keros Therapeutics, Inc. 8-K

What Happened

• Keros Therapeutics, Inc. (KROS) filed a Form 8‑K on May 14, 2026 to announce its financial results for the quarter ended March 31, 2026. The company furnished a press release announcing those results as Exhibit 99.1 to the filing.

Key Details

• Filing date: May 14, 2026 (Form 8‑K, Item 2.02: Results of Operations and Financial Condition).
• Reporting period: quarter ended March 31, 2026.
• The press release with the detailed quarterly results is furnished as Exhibit 99.1 and is incorporated by reference in the 8‑K.

Why It Matters

• This 8‑K is the company’s formal public disclosure of its quarterly financial performance; the press release (Exhibit 99.1) will contain the specific figures—revenue, net income or loss, and any management commentary or guidance—that investors use to evaluate Keros’s recent operating and financial condition.
• Retail investors should read the press release and related filings to see the actual results and any commentary that could affect the stock’s outlook or near-term trading.